KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $201.6 million.

  • Biomarin Pharmaceutical's Share-based Compensation rose 13.28% to $49.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $186.4 million, marking a year-over-year decrease of 8.85%. This contributed to the annual value of $201.6 million for FY2024, which is 2.67% down from last year.
  • According to the latest figures from FY2024, Biomarin Pharmaceutical's Share-based Compensation is $201.6 million, which was down 2.67% from $207.1 million recorded in FY2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Share-based Compensation peaked at $207.1 million during FY2023, and registered a low of $189.7 million during FY2020.
  • Moreover, its 3-year median value for Share-based Compensation was $201.6 million (2024), whereas its average is $201.7 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first increased by 18.67% in 2020, then decreased by 2.67% in 2024.
  • Biomarin Pharmaceutical's Share-based Compensation (Yearly) stood at $189.7 million in 2020, then climbed by 3.98% to $197.3 million in 2021, then dropped by 0.48% to $196.3 million in 2022, then rose by 5.50% to $207.1 million in 2023, then dropped by 2.67% to $201.6 million in 2024.